7080 related articles for article (PubMed ID: 15125569)
1. Melanoma vaccine based on the vector of membrane fusogenic liposomes.
Qiang L; Yi J; Fu-De C
Pharmazie; 2004 Apr; 59(4):263-7. PubMed ID: 15125569
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immune responses induced by vaccine using Sendai virosomes as carrier.
Li Q; Gao JQ; Qiu LY; Cui FD; Jin Y
Int J Pharm; 2007 Feb; 329(1-2):117-21. PubMed ID: 17046184
[TBL] [Abstract][Full Text] [Related]
3. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
Schirrmacher V; Haas C; Bonifer R; Ertel C
Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion.
Linardakis E; Bateman A; Phan V; Ahmed A; Gough M; Olivier K; Kennedy R; Errington F; Harrington KJ; Melcher A; Vile R
Cancer Res; 2002 Oct; 62(19):5495-504. PubMed ID: 12359759
[TBL] [Abstract][Full Text] [Related]
5. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
7. A novel vaccine delivery system using immunopotentiating fusogenic liposomes.
Hayashi A; Nakanishi T; Kunisawa J; Kondoh M; Imazu S; Tsutsumi Y; Tanaka K; Fujiwara H; Hamaoka T; Mayumi T
Biochem Biophys Res Commun; 1999 Aug; 261(3):824-8. PubMed ID: 10441509
[TBL] [Abstract][Full Text] [Related]
8. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
Riemann H; Takao J; Shellman YG; Hines WA; Edwards CK; Franzusoff A; Norris DA; Fujita M
Exp Dermatol; 2007 Oct; 16(10):814-22. PubMed ID: 17845213
[TBL] [Abstract][Full Text] [Related]
9. Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release.
Kunisawa J; Masuda T; Katayama K; Yoshikawa T; Tsutsumi Y; Akashi M; Mayumi T; Nakagawa S
J Control Release; 2005 Jul; 105(3):344-53. PubMed ID: 15936842
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.
Errington F; Bateman A; Kottke T; Thompson J; Harrington K; Merrick A; Hatfield P; Selby P; Vile R; Melcher A
Clin Cancer Res; 2006 Feb; 12(4):1333-41. PubMed ID: 16489091
[TBL] [Abstract][Full Text] [Related]
11. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
12. Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome.
Dwivedi V; Vasco A; Vedi S; Dangi A; Arif K; Bhattacharya SM; Owais M
Vaccine; 2009 Jan; 27(3):473-82. PubMed ID: 18996429
[TBL] [Abstract][Full Text] [Related]
13. Sperm membrane lipid liposomes can evoke an effective immune response against encapsulated antigen in BALB/c mice.
Atif SM; Salam N; Ahmad N; Hasan IM; Jamal HS; Sudhanshu A; Azevedo V; Owais M
Vaccine; 2008 Oct; 26(46):5874-82. PubMed ID: 18789993
[TBL] [Abstract][Full Text] [Related]
14. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
[TBL] [Abstract][Full Text] [Related]
15. [Application of novel drug delivery system, fusogenic liposome, for cancer therapy].
Kunisawa J; Mayumi T
Gan To Kagaku Ryoho; 2001 May; 28(5):577-83. PubMed ID: 11383204
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development.
Kunisawa J; Nakagawa S; Mayumi T
Adv Drug Deliv Rev; 2001 Nov; 52(3):177-86. PubMed ID: 11718942
[TBL] [Abstract][Full Text] [Related]
17. Role of fusogenic non-PC liposomes in elicitation of protective immune response against experimental murine salmonellosis.
Ahmad N; Deeba F; Faisal SM; Khan A; Agrewala JN; Dwivedi V; Owais M
Biochimie; 2006 Oct; 88(10):1391-400. PubMed ID: 16765503
[TBL] [Abstract][Full Text] [Related]
18. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
19. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
20. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
